| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Center for Research in Population Health, National Institute of Public Health, Cuernavaca, Morelos, Mexico [E. S-M., E. C. L-P., M. H-A.], and Mexican Institute of Social Security [E. S-M., J. S-C.] and Gynecology and Obstetrics Hospital No. 4, "Dr. Luis Castelazo Ayala" [G. G. L-L., P. E-D. L. R.], Mexico City, Mexicom
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Several studies assessing risk factors for these pathologies have reported consistent results in regard to pregnancies (4, 5, 6, 7) . The observation that OC is more prevalent among nulliparous women has served as a basis for the hypothesis that repeated ovulatory activity might lead to a carcinogenic effect on the epithelium of the ovary (8) . As for EC, it has been suggested that during delivery, epithelial cells, including those undergoing malignant transformation, are removed by a simple mechanical exfoliative effect (9) . In countries such as Mexico, OC and EC, as well as other types of neoplasms in women, are an ever-increasing threat that may be explained, among other reasons, by increased life expectancy, a reduction in fertility or birth rate, and the fact that breastfeeding is becoming less common. The present study of a sample of Mexican women evaluates the reproductive factors and their relationship with OC and EC, establishing the similarities and differences between them.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cases.
A group of 84 cases of ovarian epithelial neoplasm and a group of 85 cases of endometrial adenocarcinoma were selected. Included in the study were women from the gynecological oncology service who, when undergoing radiological imaging, ultrasound, or tomography, showed clinical suspicion of ovarian or endometrial cancer that was later confirmed with a biopsy-positive result. All cases were incident and had received no treatment for the condition prior to the study. The response rate in the case group was 100%.
Controls.
A control group of 668 women was obtained according to age by frequency matching in five-year categories (± 2.5 years) in a ratio of four to each case. These women were outpatients receiving primary care, in the same source area as the cases. The main reasons for the selected controls visiting the outpatient clinic were gastrointestinal upsets (34%), acute respiratory infections (22%), and skin diseases (19%), among others. The response rate was 93% (of 718 eligible controls; 50 declined to participate).
Data Collection.
In both cases and controls, information was collected by a standard questionnaire on risk factors and clinical histopathological records designed especially for the study. The questionnaire collected information on demographic data, gynecological and obstetrical history, consumption of oral contraceptives, and anthropometric measurements. Interviews were carried out by two standardized interviewers with experience in epidemiological studies. The histogenetic classification proposed by the WHO was used (10)
.
Statistical Analyses.
Crude and adjusted analyses were carried out by means of unconditional polytomic logistic regression (11)
, using the STATA 5.0 statistical package.3
OR with 95% CI were estimated. The final logistic models were established with the incorporating significant variables resulting from the bivariate analysis as well as other relevant biological variables.
To build the index of anovulation, a modification of the methods described by Casagrande et al. (12) and Risch et al. (13) was used, taking into account 9 months for each full-term pregnancy plus 6 months for each breast-fed child. To this figure, the number of months during which hormones were consumed within the period from the onset of menses until menopause (if still menstruating, the date of diagnosis and/or interview was used) was added. We estimated physical activity energy output expressed in METS (metabolic unit spent) according to METS/hour/week (14) and categorized it as an ongoing variable in tertiles. The body build index was established according to age groups following Sorensens suggestion (15) ; body mass index was calculated using a kg/m2 formula (16) .
| RESULTS |
|---|
|
|
|---|
There were no age differences between the cases and the controls, reflecting a successful age-frequency matching. The average scholastic level and age at menarche were similar in cases and controls. The proportion of women with at least one pregnancy in the study group was very high, 80.9% for OC and 74.1% for EC. Statistically significant differences in the number of pregnancies between women with EC (3.5 pregnancies) and the controls (4.6 pregnancies, P = 0.006) were observed. The mean age of the last pregnancy was significantly higher among the controls (26.7 years) than among OC cases (23.7 years, P = 0.04) or EC cases (22.2 years, P = 0.002). The average time of contraceptive hormones use was 7 months greater in the controls than in EC cases (5.1 months, P = 0.05). Average length of anovulation was lower in EC cases (50.3 months, P = 0.002) compared with the control group (71 months). The body mass index was greater among women with EC than among the control group (P = 0.002). The prevalence of diabetes mellitus in the control group was 5.4%, whereas among OC cases, it was 10.7%, and 22.3% in EC cases. Hypertension prevalence was 19.6% in the control group, 25% among OC cases, and 36.4% in the EC group (Table 1)
. In multivariate analyses, an inverse association between pregnancy and OC and EC risk was observed. In women with a history of seven or more full-term pregnancies, the risk of OC was five times lower (OR, 0.17; 95% CI, 0.050.54) and in that of EC, was nine times lower (OR, 0.11; 95% CI, 0.040.34) when compared with women who have never had a full-term pregnancy. The number of pregnancies showed a statistical significant trend (P < 0.001).
|
|
|
|
The length of anovulation was strongly inverse associated with OC risk (OR, 0.23; 95% CI, 0.100.50), and a clear statistically significant trend was observed (P < 0.001). A similar relationship was observed with EC risk (OR, 0.17; 95% CI, 0.080.35; trend P < 0.001) when comparing women in the highest quartile to those in the lowest (Table 5)
.
|
|
| DISCUSSION |
|---|
|
|
|---|
Full-term pregnancy and parity are the factors associated with ovarian cancer, which are the best documented. The results of meta-analyses of case-control studies carried out in the United States and Europe report a risk reduction in women with at least one full-term pregnancy, with a clear lineal relationship according to the number of pregnancies (19 , 20) . This protective effect against OC has been also reported in other follow-up (21 , 22) and mortality (23) studies. For EC, the relationship with pregnancy appears to be the same. Our results are consistent with previous studies showing a strong inverse relationship between full-term pregnancies and EC risk (4 , 24 , 25) .
Parity is associated with a protective effect against OC because it includes a cascade of endocrine factors relating to hormone production (pregnancy record and breastfeeding). Studies carried out in China, the United States, and Sweden (26, 27, 28) have found that the number of children significantly reduces the risk of OC. In our investigation, parity was shown to be strongly inversely related to OC risk. A similar relationship was observed for EC risk, and these results are consistent with previous reports (4 , 25) .
Pregnancies that are not carried to term appear to be inversely related to the risk of OC. Pooled analyses carried out in Europe and the United States report a slight decrease in risk; however, because they distinguish between spontaneous and induced abortions, the results are not comparable (19 , 20) . The relationship between abortion and EC is even more inconsistent; several investigations show no association (4 , 5 , 24 , 25) . In our study, there was no association with the number of abortions, probably because the number of women with cancer and a history of abortion is small.
The age at first and last delivery is the most frequently studied and the most controversial characteristic. In the case of OC, several studies show little or even no association (19 , 26 , 29 , 30) , whereas others indicate an inverse effect with first delivery at a later age (7 , 28) . The results of this variable are inconsistent in the case of EC; some studies show a slight relationship, whereas others show no evidence of an effect (5 , 24 , 31) . In different studies, the relationship of OC with the last birth at a later age show no relationship (7 , 21 , 32) , whereas in the case of EC, a consistently inverse relationship (5 , 24 , 31) is associated with this variable.
The majority of studies on breastfeeding and its relationship with OC show an inverse effect. Breastfeeding induces a partial inhibition of ovulation and increases the secretion of follicle-stimulating and luteinizing hormones, leading to conflicting hypotheses. Among women with a history of breastfeeding, risk of OC is lower compared with those who never breastfed their children; this association is inversely proportionate to the number of months of lactation (19 , 32, 33, 34) . Breastfeeding is related to the number of births and pregnancies and, together with other factors, to a shorter ovulation span. Because of the fact that estrogen levels are low during breastfeeding, it has been suggested that this ought to reduce the risk of EC. Nevertheless, results obtained in different countries are inconsistent and fail to show an association (6 , 35) , although recent investigations have found a protective effect at an early age (36) .
The relationship between the age at menarche and OC is controversial. Some case-control studies have found a 4-fold risk (26) when menses begin at an early age, whereas others with summary OR techniques have found this relationship to be weak or nonexistent (19) . Moreover, longitudinal studies indicate no association between OC and menarche at an early age (21 , 22) . In EC, the relationship is clearer, and the results are consistent, although there are reports that find no association (25) . Other case-control studies show that the risk increases 2-fold when menarche is at a later age (4) , and prospective studies indicate the opposite, i.e., that there is a reduction in risk when this takes place at a later age (24) . In our study, no association was found between the age at menarche and OC or EC.
The relationship between the onset of menopause at a later age and OC is one of the most researched, with no conclusive results. Pooled analyses in Europe (37) indicate a significant increase (OR, 1.9), whereas in Asia, case-control studies show no relationship (26 , 29) , as do pooled analyses in the United States (19) . Nor have follow up studies in Europe and America managed to establish a relationship between menopause at a later age and OC (21 , 22) . Evaluation of the relationship between this variable, late onset of menopause, and EC shows no association in some case-control studies (4) , whereas other more recent case-control (25) and follow-up (24) studies show a 5 and 87% increased risk, respectively.
The protective effect of combined oral contraceptives is one of the most consistent findings of the study of OC. Research in different countries has found an important reduction in risk, proportionate to the increase and length of consumption of these products (19 , 32 , 33 , 38, 39, 40, 41, 42) . Our results match these findings; we discovered a strong association between oral contraceptive use and OC risk reduction. The use of oral contraceptives has been consistently associated with an almost 50% reduction in the risk of EC, and furthermore, a dose-response gradient has been observed (43) . The protective effect of these hormone compounds persists, even after their use has been interrupted for up to 15 years (42, 43, 44, 45) . Hormone replacement therapy has not been associated with OC in any consistent manner. Some studies report no relationship (19 , 30) , others report a slightly positive relationship among certain histological subtypes (endometriod; Ref. 33 ), and cohort studies reveal an increased in the risk of fatal OC, according to the length of time during which replacement therapy is used (46) . In a meta-analysis carried out in the United States by Grady et al. (47) , it was conclusively shown that hormone replacement therapy is an important risk factor in the development of cancer of the endometrium. Our results show no association, probably due to the fact that prevalence of hormone replacement therapy among the study group was very low, which prevents its evaluation.
The time span of ovulation is the result of different contributing endocrinological factors. As such, more than as an individual function of each of its components, it is related with an increase of OC (26 , 29 , 48 , 49) and EC risk (24) in proportion to the number of years during which a woman ovulates.
In our study, a clear endocrine protective factor for both types of neoplasms was found. Our results are consistent with those of previous studies and support currently accepted hypotheses that typify OC and EC as hormone-dependent conditions. In the case of OC, the ovulation hypothesis indicates that any factor that suppresses this function has a protective effect. In EC, the reduction of risk is explained by: (a) the exfoliation hypothesis, i.e., the removal of epithelial cells from the endometrium during each delivery; and (b) the decrease in endogenic estrogens, as during breastfeeding. These mechanisms, and perhaps others yet to be accounted for, determine the level of risk for both OC and EC.
| FOOTNOTES |
|---|
1 To whom requests for reprints should be addressed, at Centro de Investigaciones en Salud Poblacional, Instituto Nacional de Salud Pública, Dirección de Epidemiología, Avenida Universidad No. 655, Colonia Sta. Ma. Ahuacatitlán, C. P. 62508, Cuernavaca, Morelos, México. E-mail: esalazar{at}insp3.insp.mx ![]()
2 The abbreviations used are: OC, ovarian cancer; EC, endometrial cancer; OR, odds ratio; CI, confidence interval. ![]()
3 Stata Corporation, 702 University Drive East, College Station, TX 77840. Phone: 800-STATA-PC; E-mail: Stata{at}stata.com; Internet: http. //www.stata.com. ![]()
Received 11/16/98. Accepted 6/ 4/99.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. M. Greiser, E. M. Greiser, and M. Doren Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis Hum. Reprod. Update, September 1, 2007; 13(5): 453 - 463. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zendehdel, O. Nyren, C.-G. Ostenson, H.-O. Adami, A. Ekbom, and W. Ye Cancer Incidence in Patients With Type 1 Diabetes Mellitus: A Population-Based Cohort Study in Sweden J Natl Cancer Inst, December 3, 2003; 95(23): 1797 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Modan, P. Hartge, G. Hirsh-Yechezkel, A. Chetrit, F. Lubin, U. Beller, G. Ben-Baruch, A. Fishman, J. Menczer, J. P. Struewing, et al. Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation N. Engl. J. Med., July 26, 2001; 345(4): 235 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Spurdle, P. M. Webb, D. M. Purdie, X. Chen, A. Green, and G. Chenevix-Trench Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype Carcinogenesis, January 1, 2001; 22(1): 67 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Smith, A. C. von Eschenbach, R. Wender, B. Levin, T. Byers, D. Rothenberger, D. Brooks, W. Creasman, C. Cohen, C. Runowicz, et al. American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001--Testing for Early Lung Cancer Detection CA Cancer J Clin, January 1, 2001; 51(1): 38 - 75. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |